Lantern Pharma to Showcase AI-Driven Oncology Pipeline at ThinkEquity Conference

Lantern Pharma, an artificial intelligence company developing cancer therapies, announced its management team will present at the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental in New York. The presentation will highlight the company's progress in using AI to transform oncology drug discovery and development. This matters because the company's approach represents a fundamental shift in how cancer therapies are discovered and developed, potentially reducing both the time and cost traditionally associated with bringing new oncology treatments to market. The implications are significant for patients, as accelerated development could provide life-changing therapies to hundreds of thousands of cancer patients worldwide by speeding up the creation of targeted treatments.

The company's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and utilizes more than 200 advanced ML algorithms to address significant challenges in cancer drug development. This technological foundation enables Lantern Pharma to identify and advance promising drug candidates more efficiently than conventional methods. The full scope of the company's development activities and platform capabilities can be reviewed in their corporate newsroom at https://ibn.fm/LTRN. The platform's ability to analyze vast datasets allows for the identification of novel drug targets and the optimization of existing compounds, which could lead to more effective and personalized cancer therapies.

Lantern Pharma's growing pipeline includes multiple development programs spanning various cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently has a Phase 2 clinical program and multiple Phase 1 clinical trials underway. This diversified pipeline underscores the broad applicability of its AI platform across different types of cancer, potentially addressing unmet medical needs in oncology. The potential market impact of Lantern Pharma's AI-driven pipeline is substantial, with estimated combined annual market potential exceeding $15 billion. This economic significance highlights the commercial viability of AI in drug development, attracting investor interest and funding for further research.

The company's presentation at the ThinkEquity Conference will provide investors and industry observers with insights into how artificial intelligence is reshaping cancer drug development and creating new opportunities for addressing unmet medical needs in oncology. Additional details about the conference presentation and the company's broader strategic initiatives are available through the official press release at https://ibn.fm/QSF41. The conference presentation represents an important opportunity for the company to demonstrate how its AI platform is advancing multiple therapeutic candidates through clinical development while potentially setting new standards for efficiency in oncology research. By showcasing real-world progress, Lantern Pharma aims to validate the role of AI in overcoming traditional bottlenecks in drug development, such as high failure rates and lengthy timelines, which could inspire broader adoption of similar technologies across the pharmaceutical industry.